NCT05257408: Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
- State
- Under way
- Phase
- Phase 3
- People
- 381 taking part
- Started
- 29 Jun 2022
- Primary completion
- 31 Mar 2025
- Arms
- Relacorilant 150 mg With Nab-paclitaxel 80 mg/m^2
- Results
- Posted on the registry
- 25 Feb 2022: Trial registered
- 29 Jun 2022: Trial started
- 25 Sep 2026: Trial results posted